Skip to main content
Go to the home page of the European Commission (opens in new window)
English en
CORDIS - EU research results
CORDIS

Mechanical Immunoengineering for Enhanced T-cell Immunotherapy

Project description

Advanced cell-based immunotherapy against solid tumours

T cells engineered to express chimeric antigen receptors (CAR T cells) have shown encouraging results against haematological malignancies. However, the immunosuppressive environment of solid tumours prevents CAR T cells from reaching the tumour site, necessitating enhancement strategies. The EU-funded MechanoIMM project proposes to exploit biophysical and mechanical cues to modulate antitumour immunity. Researchers will design nanoparticles that respond to the mechanical cues of tumours and deliver T cell-supporting drugs. Moreover, they will engineer T cells that can discriminate between the stiffness of the tumour and healthy tissues, thereby improving the specificity of the cell therapy.

Objective

Cancer immunotherapy harnessing the power of a patient’s immune system to fight cancer is transforming the standard-of-care for cancer. Adoptive cell therapy (ACT), a potent immunotherapy that directly infuses a large number of tumour-reactive T cells into patients, has elicited dramatic clinical responses in leukaemia patients recently. However, solid tumour remains a major challenge as tumour employs a number of strategies to prevent effector T cells reaching the tumour sites and attacking cancer by generating a highly immunosuppressive microenvironment. Current strategies are focused on controlling the immune system or the microenvironment using biochemical immunomodulatory reagents to enhance T cell based immunotherapy. Approaches exploiting biophysical and mechanical cues for immunomodulation are largely underappreciated. In this proposal, we aim to exploit mechanical immunoengineering strategies through biophysical cues to develop novel immune related treatments to enhance the efficacy and safety of adoptive T cell therapy for cancer. We will first develop a mechano-training approach to promote the T cell infiltration into tumour tissues using engineered microfluidic system for controlled force application on T cells in a high through-put manner. Second, we will develop a mechano-responsive nanoparticle delivery system to selectively deliver T-cell-supporting drugs in tumour to overcome the immune suppression in the microenvironment and enhance T cell functions for killing cancer. Third, we will develop mechano-inducible cytokine-secreting T cell therapies to augment the efficacy and minimize the toxicity of ACT by exploiting and targeting the difference in tissue stiffness between tumour and healthy tissues. This proposed project will open a new horizon for immunoengineering through biomechanical modulation of immunity for enhanced cancer immunotherapy and provide insight into the fundamentals of mechanotransduction in immune system in health and disease.

Fields of science (EuroSciVoc)

Keywords

Programme(s)

Topic(s)

Funding Scheme

ERC-STG - Starting Grant

See all projects funded under this funding scheme

Call for proposal

(opens in new window) ERC-2018-STG

See all projects funded under this call

Host institution

ECOLE POLYTECHNIQUE FEDERALE DE LAUSANNE
Net EU contribution
€ 1 499 800,00
Address
BATIMENT CE 3316 STATION 1
1015 Lausanne
Switzerland
Region
Schweiz/Suisse/Svizzera Région lémanique Vaud
Activity type
Higher or Secondary Education Establishments
Links
Total cost
€ 1 499 800,00

Beneficiaries (1)